CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jun 19, 2024Edaravone Suspension For Oral Administration1
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter2
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors1
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis1
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als1

Top competitors of Mitsubishi Tanabe Pharma

Top competitors of Mitsubishi Tanabe Pharma based on patent oppositions.